Sanguine Therapeuticz Profile
Key Indicators
- Authorised Capital ₹ 7.01 Cr
as on 31-10-2024
- Paid Up Capital ₹ 7.00 Cr
as on 31-10-2024
- Company Age 4 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 40.00 Cr
as on 31-10-2024
- Revenue -78.57%
(FY 2023)
- Profit 100.59%
(FY 2023)
- Ebitda 97.88%
(FY 2023)
- Net Worth 77.01%
(FY 2023)
- Total Assets 52.26%
(FY 2023)
About Sanguine Therapeuticz
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 7.01 Cr and a paid-up capital of Rs 7.00 Cr.
The company currently has active open charges totaling ₹40.00 Cr.
Rakesh Agarwal, Mukesh Agarwal, and Alkesh Rami serve as directors at the Company.
- CIN/LLPIN
U24100GJ2020PTC115481
- Company No.
115481
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Aug 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Surat, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Sanguine Therapeuticz?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mukesh Agarwal  | Director | 12-Aug-2020 | Current |
| Rakesh Agarwal | Director | 12-Aug-2020 | Current |
| Alkesh Rami | Director | 20-Jul-2021 | Current |
Financial Performance of Sanguine Therapeuticz.
Sanguine Therapeuticz Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 78.57% decrease. The company also saw a substantial improvement in profitability, with a 100.59% increase in profit. The company's net worth Soared by an impressive increase of 77.01%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sanguine Therapeuticz?
In 2023, Sanguine Therapeuticz had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ekdanta Fabrics Private LimitedActive 4 years 1 dayRakesh Agarwal and Mukesh Agarwal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 22 Dec 2021 | ₹20.00 Cr | Open |
Others Creation Date: 14 Dec 2021 | ₹20.00 Cr | Open |
How Many Employees Work at Sanguine Therapeuticz?
Sanguine Therapeuticz has a workforce of 9 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sanguine Therapeuticz, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sanguine Therapeuticz's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
